← Leaderboards
Nilufer Ertekin-Taner
Mayo Clinic Jacksonville
$28,054,444
Attributed
$34,360,037
Total exposure
15
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $14.6M · FY2007–25$20M$15M$10M$5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$84,270,256 · 17
By mechanism
U19$31,840,874 · 5
U01$25,862,650 · 3
RF1$9,815,712 · 1
R01$8,385,307 · 3
KL2$6,298,792 · 1
P50$845,763 · 1
Top collaborators
- Todd E. Golde19 shared
- Nathan D Price15 shared
- Steven G Younkin9 shared
- Guojun Bu5 shared
- Cory Funk4 shared
- Minerva Maria Carrasquillo3 shared
- Kwangsik Timothy Nho3 shared
- Andrew J Saykin3 shared
Most similar at Mayo Clinic Jacksonville
Same institution · by research overlap
- Andrew J Saykin$38,010,806
- Minerva Maria Carrasquillo$3,563,038
- Samuel O. Antwi$828,880
- Kwangsik Timothy Nho$9,507,789
- Lara M Mangravite$9,274,560
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposBrainS DiseaseGeneticSamplingGenesBiologicalMolecularPathologyCohortTherapeutic TargetS Disease RiskBasePathway InteractionsNerve DegenerationAutopsyClinicTau ProteinsGenetic Risk FactorPhenotypeValidationNeuropathologyGenotypeNatural Immunity
Grant awards (64)
Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations$9,157,485
U19 · FY2025 · AG · contact PI
Institutional Career Development Core$2,035,381
KL2 · FY2025 · TR · contact PI
Administrative Core$1,526,250
U19 · FY2025 · AG · contact PI
Discovering Centrally Linked Peripheral Molecular Signatures of Alzheimer's Disease$1,526,247
U19 · FY2025 · AG · contact PI
Genomic Core$330,659
P30 · FY2025 · AG · contact PI
Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations$8,291,222
U19 · FY2024 · AG · contact PI
Institutional Career Development Core$1,823,703
KL2 · FY2024 · TR · contact PI
Discovering Centrally Linked Peripheral Molecular Signatures of Alzheimer's Disease$972,232
U19 · FY2024 · AG · contact PI
Administrative Core$615,601
U19 · FY2024 · AG · contact PI
Genomic Core$330,659
P30 · FY2024 · AG · contact PI
Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations$8,248,338
U19 · FY2023 · AG · contact PI
Institutional Career Development Core$1,044,375
KL2 · FY2023 · TR · contact PI
Discovering Centrally Linked Peripheral Molecular Signatures of Alzheimer's Disease$975,754
U19 · FY2023 · AG · contact PI
Administrative Core$527,745
U19 · FY2023 · AG · contact PI
A Systems Approach to Targeting Innate Immunity in AD$2,421,378
U01 · FY2022 · AG · contact PI
Institutional Career Development Core$1,395,333
KL2 · FY2022 · TR · contact PI
Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in AD$1,130,445
R01 · FY2022 · AG · contact PI
Integrating the exposome and methylome to inform brain molecular changes in ADRD across established diverse cohorts.$988,968
U01 · FY2022 · AG · contact PI
A Systems Approach to Targeting Innate Immunity in AD$391,250
U01 · FY2022 · AG · contact PI
A Systems Approach to Targeting Innate Immunity in AD$3,188,314
U01 · FY2021 · AG · contact PI
Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in AD$1,130,445
R01 · FY2021 · AG · contact PI
A Systems Approach to Targeting Innate Immunity in AD$3,233,653
U01 · FY2020 · AG · contact PI
A Systems Approach to Targeting Innate Immunity in AD$1,197,976
U01 · FY2020 · AG
ConProject-001$1,197,976
U01 · FY2020 · AG
Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in AD$1,130,444
R01 · FY2020 · AG · contact PI
A Systems Approach to Targeting Innate Immunity in AD$455,584
U01 · FY2020 · AG · contact PI
A Systems Approach to Targeting Innate Immunity in AD$451,500
U01 · FY2020 · AG
ConProject-001$451,500
U01 · FY2020 · AG
A Systems Approach to Targeting Innate Immunity in AD$1,586,898
U01 · FY2019 · AG
Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in AD$1,130,445
R01 · FY2019 · AG · contact PI
Integrative translational discovery of vascular risk factors in aging and dementia$249,412
RF1 · FY2019 · AG · contact PI
Identification of Peripheral Transcripts as Predictive Biomarkers in Alzheimerâs Disease (AD)$197,184
U01 · FY2019 · AG
Integrative translational discovery of vascular risk factors in aging and dementia$163,895
RF1 · FY2019 · AG · contact PI
A Systems Approach to Targeting Innate Immunity in AD$1,613,148
U01 · FY2018 · AG
Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in AD$1,144,570
R01 · FY2018 · AG · contact PI
Integrative translational discovery of vascular risk factors in aging and dementia$3,577,700
RF1 · FY2017 · AG · contact PI
A system approach to targeting innate immunity in AD$1,765,056
U01 · FY2017 · AG
Gene discovery in PSP by transcriptome, neuropathology and sequence analysis$342,344
R01 · FY2017 · NS · contact PI
A system approach to targeting innate immunity in AD$1,592,165
U01 · FY2016 · AG
Integrative translational discovery of vascular risk factors in aging and dementia$497,395
RF1 · FY2016 · AG · contact PI
Gene discovery in PSP by transcriptome, neuropathology and sequence analysis$342,344
R01 · FY2016 · NS · contact PI
Genetic and Functional Analysis of Nested AD Risk Genes CTNNA3 and LRRTM3$195,625
R21 · FY2016 · AG
A system approach to targeting innate immunity in AD$156,500
U01 · FY2016 · AG
Integrative translational discovery of vascular risk factors in aging and dementia$5,327,310
RF1 · FY2015 · AG · contact PI
A system approach to targeting innate immunity in AD$1,597,190
U01 · FY2015 · AG
Gene discovery in PSP by transcriptome, neuropathology and sequence analysis$342,344
R01 · FY2015 · NS · contact PI
Genetic and Functional Analysis of Nested AD Risk Genes CTNNA3 and LRRTM3$234,750
R21 · FY2015 · AG
Gene discovery in PSP by transcriptome, neuropathology and sequence analysis$78,250
R01 · FY2015 · NS · contact PI
A system approach to targeting innate immunity in AD$1,665,226
U01 · FY2014 · AG
Gene discovery in PSP by transcriptome, neuropathology and sequence analysis$338,921
R01 · FY2014 · NS · contact PI
A system approach to targeting innate immunity in AD$109,143
U01 · FY2014 · AG
A system approach to targeting innate immunity in AD$1,602,041
U01 · FY2013 · AG
Gene discovery in PSP by transcriptome, neuropathology and sequence analysis$342,344
R01 · FY2013 · NS · contact PI
IDENTIFICATION OF AD RISK VARIANTS BY GENOME WIDE ASSOCIATION OF GENE EXPRESSIO$142,398
P50 · FY2013 · AG · contact PI
IDENTIFICATION OF AD RISK VARIANTS BY GENOME WIDE ASSOCIATION OF GENE EXPRESSIO$166,332
P50 · FY2012 · AG · contact PI
Genome wide association study of gene expression levels in Alzheimer's disease$298,139
R01 · FY2011 · AG · contact PI
IDENTIFICATION OF AD RISK VARIANTS BY GENOME WIDE ASSOCIATION OF GENE EXPRESSIO$164,367
P50 · FY2011 · AG · contact PI
Genome wide association study of gene expression levels in Alzheimer's disease$310,080
R01 · FY2010 · AG · contact PI
IDENTIFICATION OF AD RISK VARIANTS BY GENOME WIDE ASSOCIATION OF GENE EXPRESSIO$181,415
P50 · FY2010 · AG · contact PI
Genome wide association study of gene expression levels in Alzheimer's disease$324,192
R01 · FY2009 · AG · contact PI
IDENTIFICATION OF AD RISK VARIANTS BY GENOME WIDE ASSOCIATION OF GENE EXPRESSIO$191,251
P50 · FY2009 · AG · contact PI
Mapping Novel Genes for Late-Onset Alzheimer's Disease$19,345
F32 · FY2008 · AG · contact PI
Mapping Novel Genes for Late-Onset Alzheimer's Disease$58,036
F32 · FY2007 · AG · contact PI
Mapping Novel Genes for Late-Onset Alzheimer's Disease$52,084
F32 · FY2002 · AG